Neurofibromatosis type 1 (NF1)

Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1

Authors: Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, Allison Del Castillo, Maegan D Sady, Tess Inker, Marie Claire Roderick, Staci Martin, Mary Anne Toledo-Tamula, Kari Struemph, Iris Paltin, Victoria Collier, Kathy Mullin, Michael J Fisher, Roger J Packer

Journal: Neurology. Genetics

Year Published: 2021

Background and objectives Neurofibromatosis type 1 (NF1)-associated cognitive impairments carry significant lifelong morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first […]

Back to Publications

Cogstate
© 2024 Cogstate Ltd.

Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.